ENTER LEE&ZU

Wuhan Ximo Pharmaceutical Co., Ltd. (hereinafter referred to as "Simo Pharmaceutical") was established in 2013. It is a specialized, refined, unique, and innovative pharmaceutical enterprise in China's pharmaceutical industry, deeply engaged in the field of skeletal diseases. Upholding the mission of "creating high-quality drugs to safeguard skeletal health", the company has established a full-chain innovation system covering clinical demand insight, innovative drug research and development, and the transformation of research achievements into industry. It has formed a "three-in-one" research and development framework guided by clinical value and deeply integrated with industry, academia, and research, continuously delivering breakthrough diagnostic and treatment solutions in the field of skeletal diseases.

EXPERT ENDORSEMENT

Inventor of water-soluble calcium carbonate D3 preparation

Founder of the "Lizhizhu" brand, with over 28 years of experience in the field of calcium nutrition

The core product, Compound Calcium Carbonate Granules, serves as a benchmark for the company's independent innovation. It was approved for marketing by the National Medical Products Administration in June 2017 (National Medical Product Approval Number H20173214). In December 2018, the Lizhi Zhu® brand was selected as the top "Most Promising Orthopedic Drug in the Market - Golden Brick Product".